Loading

Please wait...

Ery-tab

Generic Name: erythromycin (oral) (er ITH roe MYE sin)
Brand Names: Ery-Tab
Ery-Tab (erythromycin) is used to treat many different types of infections caused by bacteria. Includes Ery-Tab side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Ery-tab

Set your location
for drug prices near you

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Ery-Tab is a delayed release tablet containing either 250 mg, 333 mg, or 500 mg of Erythromycin as the free base. Erythromycin belongs to a group of drugs called macrolide antibiotics. Macrolide antibiotics slow the growth of, or sometimes kill, sensitive bacteria by reducing the production of important proteins needed by the bacteria to survive. Ery-Tab is used to treat or prevent many different types of infections caused by bacteria. Ery-Tab may also be used for purposes not listed in this medication guide. Learn more

Ery-tab Side Effects

Ery-Tab Side Effects

Note: This document contains side effect information about erythromycin. Some of the dosage forms listed on this page may not apply to the brand name Ery-Tab.

For the Consumer

Applies to erythromycin: oral capsule delayed release, oral powder for suspension, oral tablet, oral tablet delayed release, oral tablet enteric coated

Other dosage forms:

  • intravenous powder for solution

Warning

Oral route (Suspension)

Erythromycin estolate is contraindicated in patients with preexisting liver disease. Hepatic dysfunction with or without jaundice has occurred, mainly in adults. It may be accompanied by malaise, nausea, vomiting, abdominal colic, fever, and in some instances, severe abdominal pain may lead to an abdominal surgical emergency. Discontinue erythromycin promptly if the above findings occur.

Along with its needed effects, erythromycin (the active ingredient contained in Ery-Tab) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking erythromycin:

Rare

  • Blistering, peeling, or loosening of the skin
  • chills
  • cough
  • diarrhea
  • difficulty with swallowing
  • dizziness
  • fast heartbeat
  • hives or welts, skin rash
  • joint or muscle pain
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • red, irritated eyes
  • red skin lesions, often with a purple center
  • redness of the skin
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • tightness in the chest
  • unusual tiredness or weakness

Incidence not known

  • Bloating
  • bloody or cloudy urine
  • chest pain or discomfort
  • dark urine
  • diarrhea, watery and severe, which may also be bloody
  • fainting
  • fever
  • general tiredness and weakness
  • greatly decreased frequency of urination or amount of urine
  • hearing loss
  • increased thirst
  • irregular heartbeat recurrent
  • irregular or slow heart rate
  • light-colored stools
  • nausea
  • pain
  • stomach cramp or tenderness
  • swelling of the feet or lower legs
  • unusual weight loss
  • upper right abdominal or stomach pain
  • vomiting
  • yellow eyes and skin

Some side effects of erythromycin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

  • Diarrhea (mild)
  • loss of appetite
  • weight loss

For Healthcare Professionals

Applies to erythromycin: compounding powder, injectable powder for injection, oral capsule, oral delayed release capsule, oral delayed release tablet, oral granule for reconstitution, oral suspension, oral tablet, oral tablet chewable, oral tablet coated particles

General

The most common side effects associated with oral erythromycin (the active ingredient contained in Ery-Tab) were gastrointestinal and were dose-related.

Gastrointestinal

Onset of pseudomembranous colitis symptoms has been reported during or after antibacterial therapy.

Rare (less than 0.1%): Pancreatitis, pancreatitis without biliary obstruction

Frequency not reported: Nausea, abdominal pain, diarrhea, vomiting, anorexia, infantile hypertrophic pyloric stenosis, pseudomembranous colitis, Clostridium difficile associated diarrhea (ranging from mild diarrhea to fatal colitis)

Cardiovascular

Life-threatening episodes of ventricular tachycardia associated with prolonged QT interval (torsades de pointes) have been reported following IV administration of erythromycin (the active ingredient contained in Ery-Tab) lactobionate.

QT prolongation has been reported both in otherwise healthy patients and in patients with a history of heart disease or who were on other potentially arrhythmogenic drugs. Most affected patients were receiving erythromycin intravenously. In a recent retrospective study of 278 consecutive patients who had received IV erythromycin lactobionate, 39% of 49 evaluable patients developed moderate to severe delay in ventricular repolarization (QTc interval greater than or equal to 500 msec) during treatment. Of the 278 patients, torsade de pointes was observed in one patient (less than 0.4%).

Arrhythmias and hypotension have been reported following IV administration.

One case of erythromycin-related polymorphous ventricular tachycardia reported in a patient treated for pneumonia was characterized by a normal QT interval.

Frequency not reported: QT prolongation, ventricular arrhythmias, ventricular tachycardia, torsades de pointes, arrhythmias, hypotension, polymorphous ventricular tachycardia

Postmarketing reports: Torsades de pointes

Hepatic

Rare (less than 0.1%): Hepatotoxicity, fulminant hepatic necrosis, false isolated elevations of serum glutamic oxaloacetic transaminase (SGOT) enzymes

Frequency not reported: Hepatic dysfunction (including increased liver enzymes), hepatocellular and/or cholestatic hepatitis (with or without jaundice), transient elevations of liver function tests, hepatitis, abnormal liver function test results, intrahepatic cholestasis

Hepatic dysfunction (including increased liver enzymes) and hepatocellular and/or cholestatic hepatitis (with or without jaundice) have been reported with oral erythromycin.

Hypersensitivity

Frequency not reported: Allergic reactions (ranging from urticaria to anaphylaxis), hypersensitivity reactions (presented as rash, eosinophilia, fever), hypersensitivity with noninfectious hepatitis

Dermatologic

Rare (less than 0.1%): Skin rash, maculopapular rashes (generalized, pruritic)

Frequency not reported: Skin reactions (ranging from mild eruptions to erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis)

Nervous system

Rare (less than 0.1%): Convulsions, reversible hearing loss, reversible ototoxicity

Frequency not reported: Exacerbation of myasthenia gravis symptoms, new onset of myasthenic syndrome

Reversible hearing loss was reported primarily in patients with renal dysfunction and in patients receiving high doses of erythromycin.

Several published reviews have indicated that ototoxicity was associated with erythromycin dosages greater than 4 grams per day, preexisting liver or kidney disease, and advanced age. Recovery generally occurred within two weeks.

Hematologic

A case of hemolytic anemia has been reported in a patient with severe underlying diseases and erythromycin-associated hepatitis.

Rare (less than 0.1%): Reversible agranulocytosis

Frequency not reported: Hemolytic anemia

Renal

Frequency not reported: Interstitial nephritis

Psychiatric

Rare (less than 0.1%): Recurrent nightmares

Local

Slow infusion of diluted erythromycin (the active ingredient contained in Ery-Tab) (continuously or intermittently over no less than 20 to 60 minutes) almost invariably alleviated venous irritation.

Rare (less than 0.1%): Venous irritation with IV administration

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Ery-tab (www.drugs.com/ery-tab.html).